51Cr-Bleomycin in the Diagnosis of Tumours of the Chest

D. Brykalski; J. Dobek; T. Pertynski; St Fajndt; M. Studniarek; K. Durski; M. Mussur

doi:10.1055/s-0038-1624281

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 1985; 24(02): 66-70
DOI: 10.1055/s-0038-1624281

Originalarbeiten – Original Articles

⁵¹Cr-Bleomycin in the Diagnosis of Tumours of the Chest

⁵¹Cr-BIeomycin in der Diagnostik von Tumoren des Thorax

Authors

D. Brykalski

¹From the Department of Nuclear Medicine (Head: Prof. Dr. hab. J. Liniecki), the Department of Radiology (Head: Prof. Dr. hab. J. Dobek) and the Cardiosurgery Clinic (Head: Doc. Dr. hab. J. Zaslonka) of the Medical School, and from the Department of Clinical Oncology (Head: Dr. St. Fajndt) of the Oncological Center, Lôdz, Poland
J. Dobek

¹From the Department of Nuclear Medicine (Head: Prof. Dr. hab. J. Liniecki), the Department of Radiology (Head: Prof. Dr. hab. J. Dobek) and the Cardiosurgery Clinic (Head: Doc. Dr. hab. J. Zaslonka) of the Medical School, and from the Department of Clinical Oncology (Head: Dr. St. Fajndt) of the Oncological Center, Lôdz, Poland
T. Pertynski

¹From the Department of Nuclear Medicine (Head: Prof. Dr. hab. J. Liniecki), the Department of Radiology (Head: Prof. Dr. hab. J. Dobek) and the Cardiosurgery Clinic (Head: Doc. Dr. hab. J. Zaslonka) of the Medical School, and from the Department of Clinical Oncology (Head: Dr. St. Fajndt) of the Oncological Center, Lôdz, Poland
St Fajndt

¹From the Department of Nuclear Medicine (Head: Prof. Dr. hab. J. Liniecki), the Department of Radiology (Head: Prof. Dr. hab. J. Dobek) and the Cardiosurgery Clinic (Head: Doc. Dr. hab. J. Zaslonka) of the Medical School, and from the Department of Clinical Oncology (Head: Dr. St. Fajndt) of the Oncological Center, Lôdz, Poland
M. Studniarek

¹From the Department of Nuclear Medicine (Head: Prof. Dr. hab. J. Liniecki), the Department of Radiology (Head: Prof. Dr. hab. J. Dobek) and the Cardiosurgery Clinic (Head: Doc. Dr. hab. J. Zaslonka) of the Medical School, and from the Department of Clinical Oncology (Head: Dr. St. Fajndt) of the Oncological Center, Lôdz, Poland
K. Durski

¹From the Department of Nuclear Medicine (Head: Prof. Dr. hab. J. Liniecki), the Department of Radiology (Head: Prof. Dr. hab. J. Dobek) and the Cardiosurgery Clinic (Head: Doc. Dr. hab. J. Zaslonka) of the Medical School, and from the Department of Clinical Oncology (Head: Dr. St. Fajndt) of the Oncological Center, Lôdz, Poland
M. Mussur

¹From the Department of Nuclear Medicine (Head: Prof. Dr. hab. J. Liniecki), the Department of Radiology (Head: Prof. Dr. hab. J. Dobek) and the Cardiosurgery Clinic (Head: Doc. Dr. hab. J. Zaslonka) of the Medical School, and from the Department of Clinical Oncology (Head: Dr. St. Fajndt) of the Oncological Center, Lôdz, Poland

Abstract

Summary

⁵¹Cr-bleomycin was used for the scintigraphic diagnosis of primary and secondary tumours of the thorax. The study was based on observations in 104 patients. The scintigraphy was performed using a gamma camera coupled to an on-line computer. Active lesions were scored using a semiquantitative scale of scores 0 to 5. Images were subdivided into 222 regions considered. In 72 of these, the presence of disease was diagnosed (64 malignant, 8 non-malignant) and 150 regions were classified as free from disease. At the decision threshold of score 2, over-all sensitivity and specificity of the scintigraphic detection of malignant tumours amounted to 97 and 79%, respectively. Inflammatory changes displayed some detectable accumulation of ⁵¹Cr-bleomycin but scores attributed to these lesions did not exceed the value of 2.

Zusammenfassung

⁵¹Cr-Bleomycin wurde für die Diagnostik von primären und sekundären Tumoren des Thorax eingesetzt. Die Studie umfaßte 104 Patienten, Die Szintigraphi wurde mit einer Gammakamera und angeschlossenem on-line Computer durchgeführt. Aktive Herde wurden bewertet, indem eine semiquantitative Punktskala von 0-5 angewandt wurde. Die Bilder wurden in 222 Felder aufgeteilt. In 72 dieser Felder wurde eine Erkrankung diagnostiziert, wobei 64 bösartig und 8 gutartig waren; 150 Felder wurden als krankheitsfrei bewertet. Bei einer Entscheidungsschwelle von 2 in der Bewertungsskala betrug die Gesamt-Sensitivität 97% und die Spezifität 79% für die szintigraphische Erkennbarkeit maligner Tumoren. Entzündliche Veränderungen zeigten eine erkennbare Anreicherung von ⁵¹Cr-Bleomycin, die in der Bewertungsskala jedoch nicht den Wert von 2 überschritt.

Full Text

References

References
1 Bialobrzeski J, Liniecki J. Radiation doses due to diagnostic application of ⁵¹Cr-bleomycin as derived from comparative biokinetic data in rats, rabbits and man. (In preparation).
2 Frederiksen P. B, Rasmussen J. W, Flindt-Egebak P, Oster-Jorgensen E. The place of ⁵⁷Co-bleomycin in the evaluation of tumours. Nucl. Med 1983; 22: 219-25.
3 Grove R. B, Reba R. C, Eckelman W. C, Goody M. Clinical evaluation of radiolabeled bleomycin for tumour detection. J. nucl. Med 1974; 15: 386-90.
4 International Commission on Radiological Protection: ICRP Publication 26. Pergamon Press; Oxford: 1977
5 Kahn P. C, Milunsky C, Dewanjee M. K, Rudders R. The place of ⁵⁷Co-bleomycin scanning in the evaluation of tumours. Amer. J. Roentgenol 1977; 129: 267-73.
6 Langhammer H, Hör G, Kempken K. Tumour scintigraphy with Gallium- 67. In: Tumour Localization with Radioactive Agents. 69-77 IAEA, Vienna: 1976
7 Liniecki J, Brykalski D, Pertynski T, Rembelska M, Durski K, Fajndt S. ⁵¹Cr-bleomycin, a new oncophilic radiopharmaceutical. II. Scintigraphic diagnosis of malignant neoplasms. Nucl. Med 1982; 21: 68-71.
8 Liniecki J, Pertynski T, Krawczykowa Z, Stçpierï J, Durski K. ⁵¹Cr-bleomycin in the diagnosis of ocular melanoma. Nucl. Med 1983; 22: 306-8.
9 Lucot H, Blasco A, Bollinelli R. et al. Apport de la bléomycine marquée par le cobalt-57 dans le diagnostic scintigraphique des tumeurs malignes endothoraciques. J. Radiol. Electrol 1976; 57: 69-78.
10 Maeda T, Kono A. Clinical evaluation of ⁵⁷Co-bleomycin for tumor imaging. In: Radioisotopic Methods in Tumor Diagnosis. Kakehi H, Orii H. The Research Project “Development of Tumor Diagnosis with Radioisotopes”, 85-94 Tokyo: 1977
11 Matsuura K, Watanabe K, Kawahira K. Tumor scanning with ⁵⁷Co-Bleomycin. Radioisotopic Methods in Tumor Diagnosis. Kakehi H, Orii H. The Research Project “Development of Tumor Diagnosis with Radioisotopes”, 69-84 Tokyo: 1977
12 Mishima T, Fujino Y, Hori K. et al. Experience of lung scans with ⁵⁷Co-Bleomycin. Jap. J. nucl. Med 1975; 12: 7-11.
13 National Commission on Radiation Protection: Protection in nuclear medicine and ultrasound diagnostic procedures in children. NCRP Report No. 73. Bethesda 1983
14 Nieweg O. E. ⁵⁷Co-Bleomycin Scintigraphy and ⁵⁵Co-Bleomycin Positron Emission Tomography. Thesis, Groningen, Drukkerij van Denderen B. V. 1983
15 Nouel J. P. Radionuclide metal-bleomycin complex for the diagnosis of cancer. GANN Monogr. Cancer Res 1976; 19: 301-16.
16 Nouel J. P, Renault H, Robert J, Jeanne C, Wicart et L. La bléomycine marquée au Co-57: Intérêt dans le diagnostic des tumeurs malignes et de leur extension. Nouv. Presse med 1972; 01: 95-8.
17 Nouel J. P, Robert J, Bertrand A. Labeled bleomycin in the diagnosis of cancer: A study containing the results of 1000 patients. In: Proc. of the First World Congress of Nuclear Medicine. 129-33 Tokyo: 1974
18 Poulose K. P, Watkins A. E, Reba R. C, Eckelman W. C, Goodyear M. Cobalt-labeled bleomycin - a new radiopharmaceutical for tumor localization. A comparative clinical evaluation with gallium citrate. J. nucl. Med 1975; 16: 839-41.
19 Rasker J. J, Beekhuis H, van de Poll M. A. P. C, Versluis A, Jurjens H, Woldring M. G. Clinical evaluation of radio-labelled bleomycin for tumor detection. Nucl. Med 1978; 17: 238-48.
20 Rasker F. A, Beekhuis H, Van de Wal A. W. et al. Cobalt-57 bleomycin scanning of hila and mediastium in patients with bronchial carcinoma: A prospective study. Thorax 1976; 31: 641-49.
21 Rasker J. J, van de Poll M. A. P. C, Beekhuis H, Woldring M. G, Nieweg H. P. Some experience with ⁵⁷Co-labeled bleomycin as a tumor-seeking agent. J. nucl. Med 1975; 16: 1058-69.
22 Rembelska M, Liniecki J. ⁵¹Crbleomycin, a new oncophilic radiopharma- transplantable tumours and organ-tissue of mice. Nucl. Med 1982; 21: 62-7.
23 Richman S. D, Levenson S. M, Jones A. E, Johnston G. S. Radionuclide studies in Hodgkin’s disease and lymphomas. Sem. nucl. Med 1975; 05: 103-18.
24 Robert J, Nouel J. P, Witz H, Bertrand et A. Intérêt de l’exploration scintigraphique à la bléomycine marquée dans le diagnostic positif et différentiel des lésions malignes pulmonaires primitives et secondaires. Rev. franc. Mal. Resp. 3 1975; (Suppl. 01) 203-12.
25 Roedler H. D, Kaul A, Hine G. J. Internai Radiation Dose in Diagnostic Nuclear Medicine. H. Hoffmann, Berlin y1978.
26 Sakurai T, Takimoto M, Tagami Y, Sanaka K, Yokoi H, Okada N. Chest scintigraphy with ⁵⁷Co-bleomycin for carcinoma of the lung. Wakayama med. Rep 1978; 20: 113-26.
27 Schober D, Marris P, Pertynski T, Zimmermann P, Börner P. Verteilungsstudien von ⁵⁷Co-Bleomycin bei Patienten mit Carcinoma colli uteri. Fortschr. Röntgenstr 1978; 128: 754-7.
28 Snyder W. S, Ford M. R, Warner G. G, Watson S. B. “S” absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet 11. Soc. Nucl. Med. New York: 1975
29 Suzuki Y, Hisada K, Hiraki T, Ando A. Clinical evaluation of tumor scanning with ⁵⁷Co-bleomycin. Radiology 1974; 113: 139-43.
30 UNSCEAR: Sources and Effects of Ionizing Radiation. United Nations, New York: 1977